Aardvark Therapeutics, Inc. (AARD) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US0029421007

Price
1.44 USD
Market cap
31.51 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Aardvark Therapeutics, Inc. financials

Fiscal year2025
Revenue0.00 USD
Operating income-62.73 m USD
EBIT-62.73 m USD
Net income-57.59 m USD
Diluted EPS – continuing operations-2.93 USD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.